News Related to Immunomodulatory Agent

Related coverage linked through entity extraction aliases.

FDA Approves Tecvayli Combo, Accepts Iberdomide NDA for Relapsed/Refractory Myeloma

Mar 06, 2026

The FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after at least one prior therapy, and accepted a new drug application for iberdomide plus daratumumab and dexamethasone with a PDUFA date of August 17, 2026.

CAR T-Cell Therapies Target BCMA and Alternative Antigens in Multiple Myeloma

Feb 28, 2026

New CAR T-cell approaches targeting BCMA and CD19 simultaneously show encouraging early results, while researchers develop control strategies for CAR-T therapies including antibody-drug conjugates.